Starting Monday, both Wegovy and Ozempic will cost $199 for the first two months, after which the treatment will cost $349 per month. That's 30 percent lower than the previous price and in line with Eli Lilly's competitor Zepbound.
The hope is also that it will make Novo Nordisk more resistant to counterfeit copies of the drugs that have grown enormously popular for their weight loss potential.
The price war was initiated by Novo Nordisk after the company lost market share to Eli Lilly in the US market, which is estimated to have a turnover of $100 billion by the end of the decade.
After an initial decline on the Copenhagen Stock Exchange, the share has recovered slightly and is down 1.4 percent for the day.
